ChloroquineV1, Main, Exploration, bibRecord, 002027

A survey of British rheumatologists’ DMARD preferences for rheumatoid arthritis

Identifieur interne : 002027 ( Main/Exploration ); précédent : 002026; suivant : 002028

A survey of British rheumatologists’ DMARD preferences for rheumatoid arthritis

Auteurs : P. Jobanputra [Royaume-Uni] ; J. Wilson [Royaume-Uni] ; K. Douglas [Royaume-Uni] ; A. Burls [Royaume-Uni]

Source :

Rheumatology [ 1462-0324 ] ; 2003.

RBID : ISTEX:84E05520A737157749D64354C2D762FB58E69B78

Abstract

Objective. To determine the current disease-modifying anti-rheumatic drug (DMARD) preferences of UK consultant rheumatologists. Methods. A questionnaire was sent in May 2002. We asked which DMARD(s) was most frequently preferred first and sought the most typical sequence of DMARDs, including DMARD combinations. Also we determined the extent to which prognostic and other factors influenced treatment choices. Comments were invited, written responses abstracted and key themes identified. Results. After two mailings, 331 (of 460; 72%) suitable questionnaires were returned. Ninety-five per cent (315/331) preferred methotrexate (154, 46.5%) or sulphasalazine (144, 43.5%) or either of these two (17, 5%) as first-choice agent. Of those who chose methotrexate first, 80% (123/154) ranked sulphasalazine second, 45% (55/123) combined sulphasalazine and methotrexate and 49% (27/55) then added hydroxychloroquine to this combination, in active disease. Of those who chose sulphasalazine first, 95% (137/144) ranked methotrexate second, 75% (113/150) preferring methotrexate monotherapy and 12% (18/150) the combination with sulphasalazine. Rheumatologists who preferred sulphasalazine first more commonly used subsequent DMARDs singly than those who started with methotrexate (P < 0.0001). Leflunomide was more commonly preferred than intramuscular gold as third choice (52/145 vs 29/145; P < 0.003). The most popular sequence of DMARDs was methotrexate or sulphasalazine, singly or in combination, leflunomide, intramuscular gold and anti-tumour necrosis factor therapy. Poor prognostic factors influenced DMARD choice, but patient occupation and drug costs did not. Conclusion. Methotrexate has displaced other DMARDs, especially sulphasalazine, as agent of first choice and newer agents have displaced older DMARDs. Whether the expressed preference for particular DMARDs accurately reflects actual use, and is optimal in rheumatoid arthritis, remains to be determined.

Url:

https://api.istex.fr/ark:/67375/HXZ-K8HP87TT-7/fulltext.pdf

DOI: 10.1093/rheumatology/keh003

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: 000289
to stream Istex, to step Curation: 000289
to stream Istex, to step Checkpoint: 000E68
to stream Main, to step Merge: 002042
to stream Main, to step Curation: 002027

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A survey of British rheumatologists’ DMARD preferences for rheumatoid arthritis</title>
<author><name sortKey="Jobanputra, P" sort="Jobanputra, P" uniqKey="Jobanputra P" first="P." last="Jobanputra">P. Jobanputra</name>
</author>
<author><name sortKey="Wilson, J" sort="Wilson, J" uniqKey="Wilson J" first="J." last="Wilson">J. Wilson</name>
</author>
<author><name sortKey="Douglas, K" sort="Douglas, K" uniqKey="Douglas K" first="K." last="Douglas">K. Douglas</name>
</author>
<author><name sortKey="Burls, A" sort="Burls, A" uniqKey="Burls A" first="A." last="Burls">A. Burls</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:84E05520A737157749D64354C2D762FB58E69B78</idno>
<date when="2004" year="2004">2004</date>
<idno type="doi">10.1093/rheumatology/keh003</idno>
<idno type="url">https://api.istex.fr/ark:/67375/HXZ-K8HP87TT-7/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000289</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000289</idno>
<idno type="wicri:Area/Istex/Curation">000289</idno>
<idno type="wicri:Area/Istex/Checkpoint">000E68</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000E68</idno>
<idno type="wicri:doubleKey">1462-0324:2004:Jobanputra P:a:survey:of</idno>
<idno type="wicri:Area/Main/Merge">002042</idno>
<idno type="wicri:Area/Main/Curation">002027</idno>
<idno type="wicri:Area/Main/Exploration">002027</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">A survey of British rheumatologists’ DMARD preferences for rheumatoid arthritis</title>
<author><name sortKey="Jobanputra, P" sort="Jobanputra, P" uniqKey="Jobanputra P" first="P." last="Jobanputra">P. Jobanputra</name>
<affiliation wicri:level="4"><orgName type="university">Université de Birmingham</orgName>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr" wicri:curation="lc">Royaume-Uni</country>
<wicri:regionArea>Department of Rheumatology, Selly Oak Hospital, University Hospital Birmingham NHS Trust, Raddlebarn Road, Birmingham B29 6JD</wicri:regionArea>
<wicri:noRegion>Birmingham B29 6JD</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wilson, J" sort="Wilson, J" uniqKey="Wilson J" first="J." last="Wilson">J. Wilson</name>
<affiliation wicri:level="4"><orgName type="university">Université de Birmingham</orgName>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Douglas, K" sort="Douglas, K" uniqKey="Douglas K" first="K." last="Douglas">K. Douglas</name>
<affiliation wicri:level="1"><country xml:lang="fr" wicri:curation="lc">Royaume-Uni</country>
<wicri:regionArea>Department of Rheumatology, Selly Oak Hospital, University Hospital Birmingham NHS Trust, Raddlebarn Road, Birmingham B29 6JD</wicri:regionArea>
<wicri:noRegion>Birmingham B29 6JD</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Burls, A" sort="Burls, A" uniqKey="Burls A" first="A." last="Burls">A. Burls</name>
<affiliation wicri:level="4"><orgName type="university">Université de Birmingham</orgName>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Rheumatology</title>
<title level="j" type="abbrev">Rheumatology</title>
<idno type="ISSN">1462-0324</idno>
<idno type="eISSN">1462-0332</idno>
<imprint><publisher>Oxford University Press</publisher>
<date type="e-published" when="2003-08-15">2003</date>
<date when="2004-02">2004</date>
<biblScope unit="vol">43</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="206">206</biblScope>
<biblScope unit="page" to="210">210</biblScope>
</imprint>
<idno type="ISSN">1462-0324</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">1462-0324</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objective. To determine the current disease-modifying anti-rheumatic drug (DMARD) preferences of UK consultant rheumatologists. Methods. A questionnaire was sent in May 2002. We asked which DMARD(s) was most frequently preferred first and sought the most typical sequence of DMARDs, including DMARD combinations. Also we determined the extent to which prognostic and other factors influenced treatment choices. Comments were invited, written responses abstracted and key themes identified. Results. After two mailings, 331 (of 460; 72%) suitable questionnaires were returned. Ninety-five per cent (315/331) preferred methotrexate (154, 46.5%) or sulphasalazine (144, 43.5%) or either of these two (17, 5%) as first-choice agent. Of those who chose methotrexate first, 80% (123/154) ranked sulphasalazine second, 45% (55/123) combined sulphasalazine and methotrexate and 49% (27/55) then added hydroxychloroquine to this combination, in active disease. Of those who chose sulphasalazine first, 95% (137/144) ranked methotrexate second, 75% (113/150) preferring methotrexate monotherapy and 12% (18/150) the combination with sulphasalazine. Rheumatologists who preferred sulphasalazine first more commonly used subsequent DMARDs singly than those who started with methotrexate (P < 0.0001). Leflunomide was more commonly preferred than intramuscular gold as third choice (52/145 vs 29/145; P < 0.003). The most popular sequence of DMARDs was methotrexate or sulphasalazine, singly or in combination, leflunomide, intramuscular gold and anti-tumour necrosis factor therapy. Poor prognostic factors influenced DMARD choice, but patient occupation and drug costs did not. Conclusion. Methotrexate has displaced other DMARDs, especially sulphasalazine, as agent of first choice and newer agents have displaced older DMARDs. Whether the expressed preference for particular DMARDs accurately reflects actual use, and is optimal in rheumatoid arthritis, remains to be determined.</div>
</front>
</TEI>
<affiliations><list><country><li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Midlands de l'Ouest</li>
</region>
<settlement><li>Birmingham</li>
</settlement>
<orgName><li>Université de Birmingham</li>
</orgName>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Jobanputra, P" sort="Jobanputra, P" uniqKey="Jobanputra P" first="P." last="Jobanputra">P. Jobanputra</name>
</region>
<name sortKey="Burls, A" sort="Burls, A" uniqKey="Burls A" first="A." last="Burls">A. Burls</name>
<name sortKey="Douglas, K" sort="Douglas, K" uniqKey="Douglas K" first="K." last="Douglas">K. Douglas</name>
<name sortKey="Jobanputra, P" sort="Jobanputra, P" uniqKey="Jobanputra P" first="P." last="Jobanputra">P. Jobanputra</name>
<name sortKey="Wilson, J" sort="Wilson, J" uniqKey="Wilson J" first="J." last="Wilson">J. Wilson</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002027 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002027 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:84E05520A737157749D64354C2D762FB58E69B78
   |texte=   A survey of British rheumatologists’ DMARD preferences for rheumatoid arthritis
}}

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Chloroquine

A survey of British rheumatologists’ DMARD preferences for rheumatoid arthritis

A survey of British rheumatologists’ DMARD preferences for rheumatoid arthritis

Source :

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri